These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
141 related articles for article (PubMed ID: 20494934)
1. Validation, revision and extension of the Mantle Cell Lymphoma International Prognostic Index in a population-based setting. van de Schans SA; Janssen-Heijnen ML; Nijziel MR; Steyerberg EW; van Spronsen DJ Haematologica; 2010 Sep; 95(9):1503-9. PubMed ID: 20494934 [TBL] [Abstract][Full Text] [Related]
2. Validation, revision and extension of the Follicular Lymphoma International Prognostic Index (FLIPI) in a population-based setting. van de Schans SA; Steyerberg EW; Nijziel MR; Creemers GJ; Janssen-Heijnen ML; van Spronsen DJ Ann Oncol; 2009 Oct; 20(10):1697-702. PubMed ID: 19549712 [TBL] [Abstract][Full Text] [Related]
3. Confirmation of the mantle-cell lymphoma International Prognostic Index in randomized trials of the European Mantle-Cell Lymphoma Network. Hoster E; Klapper W; Hermine O; Kluin-Nelemans HC; Walewski J; van Hoof A; Trneny M; Geisler CH; Di Raimondo F; Szymczyk M; Stilgenbauer S; Thieblemont C; Hallek M; Forstpointner R; Pott C; Ribrag V; Doorduijn J; Hiddemann W; Dreyling MH; Unterhalt M J Clin Oncol; 2014 May; 32(13):1338-46. PubMed ID: 24687837 [TBL] [Abstract][Full Text] [Related]
4. Prognostic Value of Ki-67 Index, Cytology, and Growth Pattern in Mantle-Cell Lymphoma: Results From Randomized Trials of the European Mantle Cell Lymphoma Network. Hoster E; Rosenwald A; Berger F; Bernd HW; Hartmann S; Loddenkemper C; Barth TF; Brousse N; Pileri S; Rymkiewicz G; Kodet R; Stilgenbauer S; Forstpointner R; Thieblemont C; Hallek M; Coiffier B; Vehling-Kaiser U; Bouabdallah R; Kanz L; Pfreundschuh M; Schmidt C; Ribrag V; Hiddemann W; Unterhalt M; Kluin-Nelemans JC; Hermine O; Dreyling MH; Klapper W J Clin Oncol; 2016 Apr; 34(12):1386-94. PubMed ID: 26926679 [TBL] [Abstract][Full Text] [Related]
5. Association of red blood cell distribution width and outcomes in patients with mantle cell lymphoma. Miao Y; Zhou XH; Guo JJ; Sun Q; Shi K; Wu JZ; Zhu HY; Wang L; Fan L; Xu W; Li JY Cancer Med; 2019 Jun; 8(6):2751-2758. PubMed ID: 30980510 [TBL] [Abstract][Full Text] [Related]
6. Retrospective analysis of 235 unselected patients with mantle cell lymphoma confirms prognostic relevance of Mantle Cell Lymphoma International Prognostic Index and Ki-67 in the era of rituximab: long-term data from the Czech Lymphoma Project Database. Salek D; Vesela P; Boudova L; Janikova A; Klener P; Vokurka S; Jankovska M; Pytlik R; Belada D; Pirnos J; Moulis M; Kodet R; Michal M; Janousova E; Muzik J; Mayer J; Trněný M Leuk Lymphoma; 2014 Apr; 55(4):802-10. PubMed ID: 23772666 [TBL] [Abstract][Full Text] [Related]
7. Nomogram incorporating clinicopathological parameters to predict the survival of patients with mantle cell lymphoma. Zhu Y; Xu W; Zheng X; Zheng Z J Investig Med; 2019 Feb; 67(2):331-337. PubMed ID: 30258027 [TBL] [Abstract][Full Text] [Related]
8. Central nervous system involvement in mantle cell lymphoma: clinical features, prognostic factors and outcomes from the European Mantle Cell Lymphoma Network. Cheah CY; George A; Giné E; Chiappella A; Kluin-Nelemans HC; Jurczak W; Krawczyk K; Mocikova H; Klener P; Salek D; Walewski J; Szymczyk M; Smolej L; Auer RL; Ritchie DS; Arcaini L; Williams ME; Dreyling M; Seymour JF; Ann Oncol; 2013 Aug; 24(8):2119-23. PubMed ID: 23616279 [TBL] [Abstract][Full Text] [Related]
9. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Hoster E; Dreyling M; Klapper W; Gisselbrecht C; van Hoof A; Kluin-Nelemans HC; Pfreundschuh M; Reiser M; Metzner B; Einsele H; Peter N; Jung W; Wörmann B; Ludwig WD; Dührsen U; Eimermacher H; Wandt H; Hasford J; Hiddemann W; Unterhalt M; ; Blood; 2008 Jan; 111(2):558-65. PubMed ID: 17962512 [TBL] [Abstract][Full Text] [Related]
10. A novel clinical immune-related prognostic model predicts the overall survival of mantle cell lymphoma. Lv H; Fei Y; Li W; Wang Y; Wang J; He J; Liu X; Li L; Qiu L; Qian Z; Zhou S; Meng B; Zhai Q; Ren X; Zou D; Cai Q; Wang X; Zhang H Hematol Oncol; 2022 Aug; 40(3):343-355. PubMed ID: 35368100 [TBL] [Abstract][Full Text] [Related]
11. Long-term survival of patients with mantle cell lymphoma after autologous haematopoietic stem-cell transplantation in first remission: a post-hoc analysis of an open-label, multicentre, randomised, phase 3 trial. Zoellner AK; Unterhalt M; Stilgenbauer S; Hübel K; Thieblemont C; Metzner B; Topp M; Truemper L; Schmidt C; Bouabdallah K; Krauter J; Lenz G; Dürig J; Vergote V; Schäfer-Eckart K; André M; Kluin-Nelemans HC; van Hoof A; Klapper W; Hiddemann W; Dreyling M; Hoster E; Lancet Haematol; 2021 Sep; 8(9):e648-e657. PubMed ID: 34450102 [TBL] [Abstract][Full Text] [Related]
12. Marked improvement of overall survival in mantle cell lymphoma: a population based study from the Swedish Lymphoma Registry. Abrahamsson A; Dahle N; Jerkeman M Leuk Lymphoma; 2011 Oct; 52(10):1929-35. PubMed ID: 21702648 [TBL] [Abstract][Full Text] [Related]
13. Prognostic relevance of clinical risk factors in mantle cell lymphoma. Hoster E Semin Hematol; 2011 Jul; 48(3):185-8. PubMed ID: 21782060 [TBL] [Abstract][Full Text] [Related]
14. Genomic aberrations in mantle cell lymphoma detected by interphase fluorescence in situ hybridization. Incidence and clinicopathological correlations. Sander S; Bullinger L; Leupolt E; Benner A; Kienle D; Katzenberger T; Kalla J; Ott G; Müller-Hermelink HK; Barth TF; Möller P; Lichter P; Döhner H; Stilgenbauer S Haematologica; 2008 May; 93(5):680-7. PubMed ID: 18367489 [TBL] [Abstract][Full Text] [Related]
15. Prognostic model for mantle cell lymphoma in the rituximab era: a nationwide study in Japan. Chihara D; Asano N; Ohmachi K; Kinoshita T; Okamoto M; Maeda Y; Mizuno I; Matsue K; Uchida T; Nagai H; Nishikori M; Nakamura S; Ogura M; Suzuki R Br J Haematol; 2015 Sep; 170(5):657-68. PubMed ID: 25953436 [TBL] [Abstract][Full Text] [Related]
16. Ki-67 expression level, histological subtype, and the International Prognostic Index as outcome predictors in mantle cell lymphoma. Räty R; Franssila K; Joensuu H; Teerenhovi L; Elonen E Eur J Haematol; 2002 Jul; 69(1):11-20. PubMed ID: 12270057 [TBL] [Abstract][Full Text] [Related]
17. Mantle cell lymphoma epidemiology: a population-based study in France. Leux C; Maynadié M; Troussard X; Cabrera Q; Herry A; Le Guyader-Peyrou S; Le Gouill S; Monnereau A Ann Hematol; 2014 Aug; 93(8):1327-33. PubMed ID: 24763513 [TBL] [Abstract][Full Text] [Related]
18. Prognostic impact of monocyte count at presentation in mantle cell lymphoma. von Hohenstaufen KA; Conconi A; de Campos CP; Franceschetti S; Bertoni F; Margiotta Casaluci G; Stathis A; Ghielmini M; Stussi G; Cavalli F; Gaidano G; Zucca E Br J Haematol; 2013 Aug; 162(4):465-73. PubMed ID: 23808798 [TBL] [Abstract][Full Text] [Related]
19. Mantle cell lymphoma: prognostic capacity of the Follicular Lymphoma International Prognostic Index. Møller MB; Pedersen NT; Christensen BE Br J Haematol; 2006 Apr; 133(1):43-9. PubMed ID: 16512827 [TBL] [Abstract][Full Text] [Related]
20. Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study. Dreyling M; Jurczak W; Jerkeman M; Silva RS; Rusconi C; Trneny M; Offner F; Caballero D; Joao C; Witzens-Harig M; Hess G; Bence-Bruckler I; Cho SG; Bothos J; Goldberg JD; Enny C; Traina S; Balasubramanian S; Bandyopadhyay N; Sun S; Vermeulen J; Rizo A; Rule S Lancet; 2016 Feb; 387(10020):770-8. PubMed ID: 26673811 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]